journal
MENU ▼
Read by QxMD icon Read
search

Cancer Treatment Reports

journal
https://www.readbyqxmd.com/read/2891441/phase-i-trial-of-taxol-in-patients-with-advanced-cancer
#1
R C Donehower, E K Rowinsky, L B Grochow, S M Longnecker, D S Ettinger
Taxol is a unique plant-derived antineoplastic agent that appears to exert its cytotoxic effect by interfering with microtubule structure and function. In this phase I trial, in which the drug was given as a brief iv infusion every 3 weeks, the dose-limiting toxicity was leukopenia, with thrombocytopenia being seen much less frequently. Sensory neuropathy was frequently seen at the highest dosage, with numbness and paresthesias appearing in a glove-and-stocking distribution. In some cases, this appeared to be a cumulative effect...
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2825994/etoposide-ifosfamide-and-cisplatin-in-the-treatment-of-advanced-non-small-cell-lung-cancer
#2
A Ardizzoni, V Fusco, M Gulisano, P Pronzato, F Baracco, A Capaccio, G Pastorino, M Nosenzo, R Felletti, F Fabiano
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2446754/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-colorectal-carcinoma-a-southwest-oncology-group-study
#3
W H Harvey, T R Fleming, D D Von Hoff, J G Katterhagen, C A Coltman
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2446753/phase-ii-trial-of-fludarabine-phosphate-in-patients-with-head-and-neck-cancer-a-southwest-oncology-group-study
#4
G B Weiss, B Metch, D D Von Hoff, S A Taylor, J H Saiers
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2445482/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-hepatoma-a-southwest-oncology-group-study
#5
W H Harvey, T R Fleming, G Beltran, J H Saiers, N Oishi, D D Von Hoff
No abstract text is available yet for this article.
November 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3038318/phase-ii-trial-of-oral-piritrexim-bw301u-in-patients-with-stage-iii-non-small-cell-lung-cancer
#6
M G Kris, R J Gralla, M T Burke, L D Berkowitz, L D Marks, D P Kelsen, R T Heelan
No abstract text is available yet for this article.
July 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2436773/evaluation-of-fludarabine-phosphate-in-renal-cell-carcinoma-a-southwest-oncology-group-study
#7
L Balducci, B Blumenstein, D D Von Hoff, M Davis, H E Hynes, R M Bukowski, E D Crawford
No abstract text is available yet for this article.
May 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3815401/phase-ii-studies-of-pcnu-and-bisantrene-in-advanced-renal-cell-carcinoma
#8
P J Elson, R H Earhart, L K Kvols, R Spiegel, A M Keller, M S Kies, T E Davis, C Stevens, L Gumas, D L Trump
No abstract text is available yet for this article.
March 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3542207/hammering-away-at-solid-tumors
#9
F R Appelbaum
No abstract text is available yet for this article.
February 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3791258/vindesine-for-recurrent-and-metastatic-cancer-of-the-uterine-cervix-a-phase-ii-study
#10
W U Rhomberg
Twenty-four patients with recurrent or metastatic cervical cancer were treated with vindesine (VDS) (2 mg/m2) on 2 subsequent days per week. Twenty patients were evaluable for response. There were six partial responses (30%) and no complete responses. The median remission duration was 6.5 months. The results indicate that VDS is active in the treatment of cervical cancer. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. VDS should be considered in the treatment planning of combination chemotherapy for cervical cancer...
December 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3791252/study-of-cardiovascular-autonomic-insufficiency-in-advanced-cancer-patients
#11
E Bruera, S Chadwick, R Fox, J Hanson, N MacDonald
To determine the incidence of cardiovascular autonomic insufficiency (CAI), 43 patients with advanced breast cancer and 20 normal controls were evaluated using electrocardiographic tests (heart rate variation during deep breathing and Valsalva maneuver and upon standing) and clinical tests (blood pressure variation during hand grip tests and upon standing). Nutritional status, tumor mass, Karnofsky performance status (PS) score (0-100), and peripheral reflexes were also determined. Tests for CAI were abnormal in 43 patients (52%), versus seven of 100 in 20 controls (7%, P less than 0...
December 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2431776/antagonism-of-5-aza-2-deoxycytidine-antileukemic-activity-by-concomitant-treatment-with-cytarabine
#12
T Colombo, C Rossi, M D'Incalci
In this study we show that cytarabine given simultaneously with 5-aza-2'-deoxycytidine (Aza-dC) antagonized Aza-dC activity against L1210 mouse leukemia. This antagonism was seen after a single dose (on Day 3 or Day 5 after tumor implant) and after repeated doses. This observation suggests caution in combining cytarabine with Aza-dC in the treatment of human leukemias.
December 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2431775/central-nervous-system-toxicity-with-fludarabine
#13
D E Merkel, N L Griffin, K Kagan-Hallet, D D Von Hoff
A serious delayed neurotoxicity marked by encephalopathy and cortical blindness has occurred in patients treated with fludarabine. This toxicity had only been reported in patients receiving high doses (ie, aplasia-inducing). We describe a similar subacute neurological deterioration occurring in two patients, including one who received only low doses of this agent. Neurologic vulnerability to low doses of fludarabine may be multifactorial and at present cannot be predicted. Continued caution in the use of this new antineoplastic agent is appropriate...
December 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3021327/clinical-trial-of-doxifluridine-in-the-treatment-of-primary-hepatocellular-carcinoma
#14
K H Lai, Y T Tsai, S D Lee, Y S Yeh, S S Wang, W W Ng, J Y Wang, T T Chiang, C S Lay, C F Yang
No abstract text is available yet for this article.
November 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2428493/phase-ii-evaluation-of-fludarabine-in-patients-with-metastatic-breast-cancer-a-southeastern-cancer-study-group-trial
#15
J T Carpenter, C L Vogel, G Wang, M Raney
No abstract text is available yet for this article.
October 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2428492/central-nervous-system-toxicity-of-fludarabine-phosphate
#16
H G Chun, B R Leyland-Jones, S M Caryk, D F Hoth
Fourteen patients developed severe central nervous system (CNS) toxicity after receiving an investigational antitumor agent, fludarabine phosphate (FAMP). The CNS toxicity has the distinctive features of delayed onset and progressive clinical course. Visual deficits were the most common presenting symptom and developed eventually in most cases. Deterioration of mental status and progressive encephalopathy were also observed. The development of clinical CNS toxicity appears dose-related; thirteen of 36 patients (36...
October 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2427196/phase-ii-study-of-fludarabine-phosphate-for-the-treatment-of-advanced-non-small-cell-carcinoma-of-the-lung-a-southwest-oncology-group-study
#17
COMPARATIVE STUDY
G R Weiss, J Crowley, D D Von Hoff, S A Taylor, R J Belt, C A Coltman, H E Hynes, J J Costanzi
No abstract text is available yet for this article.
September 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3524823/comparative-metabolism-of-daunorubicin-and-4-demethoxydaunorubicin-in-mice-and-rabbits
#18
COMPARATIVE STUDY
M Broggini, B Sommacampagna, A Paolini, E Dolfini, M G Donelli
In the present study, the biodisposition of 4-demethoxydaunorubicin (4DDM) and its 13-dihydrometabolite was compared with daunorubicin (DM) and its metabolite in rabbit serum, and the results were considered in the light of this DM analog's pharmacokinetic behavior in mice. In rabbit serum, the levels of the 13-OH derivative of both DM and 4DDM (daunorubicinol and 4-demethoxydaunorubicinol) were higher than in mice. In vitro metabolic studies with mouse and rabbit cytosol indicated that the hepatic metabolism was quantitatively important for both analogs (70%-90% for DM and 4DDM was reduced to the 13-OH metabolite), but the rabbit had a much higher specific capacity to metabolize these compounds...
June 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2942245/phase-ii-clinical-evaluation-of-doxifluridine
#19
P Hurteloup, J P Armand, P Cappelaere, R Metz, P Kerbrat, R Keiling, P Fumoleau, P Fargeot, S Schraub, P Bastit
Disease-oriented phase II trials of doxifluridine were performed in advanced colorectal, breast, renal, endometrial, stomach, and ovarian carcinomas. The dose schedule recommended by the phase I trial (12.5 g/m2 by continuous iv infusion over 6 hours once a week for 3 weeks followed by a 1-week rest) was chosen first: the initial dose was later decreased to 10 g/m2 due to the fact that several neurotoxic effects were reported. A total of 207 patients were entered: 137 patients who received at least two courses of treatment were evaluable for response...
June 1986: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2421893/pharmacologic-analysis-of-the-ip-administration-of-fludarabine-phosphate-in-the-swine
#20
G R Weiss, H V Gaskill, J L Phillips
Fludarabine phosphate, an investigational water-soluble adenosine analog, was administered ip to five miniature swine at doses of 10, 16, and 25 mg/m2. Blood and peritoneal fluid samples were collected for 4 hours following drug administration and were submitted to high-performance liquid chromatographic analysis for the concentrations of the dephosphorylated derivative, 2-fluoro-ara-A. Peak peritoneal fluid concentrations of 2-fluoro-ara-A ranged from 7.72 to 18.01 micrograms/ml at the doses tested; peritoneal fluid areas-under-the-curve (AUCs) ranged from 19...
April 1986: Cancer Treatment Reports
journal
journal
26734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"